Sign In
Buy ZYNE
$1.30
+0 (+0%)
At Close: Jan 09, 2024
Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
02:00pm, Thursday, 29'th Apr 2021
DEVON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Zynerba: Repeated Trial Failures, Some Post Hoc Success
11:22am, Tuesday, 13'th Apr 2021
ZYNE has a cannabidiol gel it is running through various trials. The company and this drug have a history of failures.
SAN DIEGO, March 28, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) ("Zynerba " or the "Company") against certain
8 Cannabis Stocks on Fire After Corporate Moves
03:53pm, Friday, 12'th Mar 2021
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will co
Zynerba's CBD skin gel Zygel offers a goldmine of therapies for Fragile X syndrome and other conditions
11:28am, Thursday, 11'th Mar 2021
Developing novel transdermal CBD treatments to treat patients suffering rare epilepsies and neurological disorders Lead development candidate Zygel offers a potential goldmine of therapies for multipl
Zynerba Pharmaceuticals says it is fully funded into 2024; lays out plans to advance four Zygel indications in 4Q results
09:34am, Wednesday, 10'th Mar 2021
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) believes its operations and capital requirements to be fully funded into 2024, the company announced as part of its fourth-quarter and full-year res
Zynerba Pharmaceuticals says its fully funded into 2024, lays out plans to advance four Zygel indications in 4Q results
09:07am, Wednesday, 10'th Mar 2021
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) believes its operations and capital req[uirements to be fully funded into 2024, the company announced as part of its fourth quarter and full-year results publ
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
06:45am, Wednesday, 10'th Mar 2021
DEVON, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
06:59pm, Friday, 05'th Mar 2021
Zynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day.
Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference
08:00am, Thursday, 04'th Mar 2021
DEVON, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
06:57pm, Friday, 26'th Feb 2021
Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day.
ZYNE Stock: Why Zynerba Pharmaceutical Shares Are Soaring Today
04:12pm, Wednesday, 10'th Feb 2021
ZYNE stock is on a roll, with investors betting its transdermal therapeutic cannabidiol gel will take off soon. The post ZYNE Stock: Why Zynerba Pharmaceutical Shares Are Soaring Today appeared first
ZYNE Stock Price Increases Over 20%: Why It Happened
02:32pm, Wednesday, 03'rd Feb 2021
The stock price of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is trading at over 20% today. This is why it happened.
Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
07:30am, Monday, 04'th Jan 2021
DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
06:30am, Thursday, 17'th Dec 2020
- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -
